Announcements
- Wave Life Sciences to Present at Upcoming Investor Conferences
- Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
- Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
- Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
- Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
- Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
More ▼
Key statistics
On Friday, WAVE Life Sciences Ltd (1U5:FRA) closed at 4.44, 40.51% above the 52 week low of 3.16 set on Jun 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.46 |
---|---|
High | 4.46 |
Low | 4.44 |
Bid | -- |
Offer | -- |
Previous close | 4.46 |
Average volume | 220.10 |
---|---|
Shares outstanding | 122.28m |
Free float | 100.02m |
P/E (TTM) | -- |
Market cap | 586.96m USD |
EPS (TTM) | -0.5397 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 14:32 BST.
More ▼